View in EDS

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.

Saved in:
Bibliographic Details
Title: Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
Authors: Knight EMP; Epilepsy Center, Cleveland Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: pestane@ccf.org., Amin S; Pediatric Neurology, University Hospitals Bristol and Weston, Bristol, UK., Bahi-Buisson N; Pediatric Neurology, Necker Enfants Malades University Hospital, Paris, France., Benke TA; Department of Pediatrics and Neurology, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, USA., Cross JH; UCL NIHR BRC Great Ormond Street Institute of Child Health, London, UK., Demarest ST; Department of Pediatrics and Neurology, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, USA., Olson HE; Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA., Specchio N; Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Fleming TR; Department of Biostatistics, University of Washington, Seattle, WA, USA., Aimetti AA; Marinus Pharmaceuticals, Radnor, PA, USA., Gasior M; Marinus Pharmaceuticals, Radnor, PA, USA., Devinsky O; New York University Langone Comprehensive Epilepsy Center, New York, NY, USA.
Corporate Authors: Marigold Trial Group
Source: The Lancet. Neurology [Lancet Neurol] 2022 May; Vol. 21 (5), pp. 417-427.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35429480
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Knight+EMP%22">Knight EMP</searchLink>; Epilepsy Center, Cleveland Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: pestane@ccf.org.<br /><searchLink fieldCode="AU" term="%22Amin+S%22">Amin S</searchLink>; Pediatric Neurology, University Hospitals Bristol and Weston, Bristol, UK.<br /><searchLink fieldCode="AU" term="%22Bahi-Buisson+N%22">Bahi-Buisson N</searchLink>; Pediatric Neurology, Necker Enfants Malades University Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Benke+TA%22">Benke TA</searchLink>; Department of Pediatrics and Neurology, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22Cross+JH%22">Cross JH</searchLink>; UCL NIHR BRC Great Ormond Street Institute of Child Health, London, UK.<br /><searchLink fieldCode="AU" term="%22Demarest+ST%22">Demarest ST</searchLink>; Department of Pediatrics and Neurology, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22Olson+HE%22">Olson HE</searchLink>; Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Specchio+N%22">Specchio N</searchLink>; Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Fleming+TR%22">Fleming TR</searchLink>; Department of Biostatistics, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Aimetti+AA%22">Aimetti AA</searchLink>; Marinus Pharmaceuticals, Radnor, PA, USA.<br /><searchLink fieldCode="AU" term="%22Gasior+M%22">Gasior M</searchLink>; Marinus Pharmaceuticals, Radnor, PA, USA.<br /><searchLink fieldCode="AU" term="%22Devinsky+O%22">Devinsky O</searchLink>; New York University Langone Comprehensive Epilepsy Center, New York, NY, USA.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22Marigold+Trial+Group%22">Marigold Trial Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101139309%22">The Lancet. Neurology</searchLink> [Lancet Neurol] 2022 May; Vol. 21 (5), pp. 417-427.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101139309 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-4465 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214744422%22">14744422 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Neurol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35429480
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1474-4422(22)00077-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 417
    Titles:
      – TitleFull: Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Knight EMP
      – PersonEntity:
          Name:
            NameFull: Amin S
      – PersonEntity:
          Name:
            NameFull: Bahi-Buisson N
      – PersonEntity:
          Name:
            NameFull: Benke TA
      – PersonEntity:
          Name:
            NameFull: Cross JH
      – PersonEntity:
          Name:
            NameFull: Demarest ST
      – PersonEntity:
          Name:
            NameFull: Olson HE
      – PersonEntity:
          Name:
            NameFull: Specchio N
      – PersonEntity:
          Name:
            NameFull: Fleming TR
      – PersonEntity:
          Name:
            NameFull: Aimetti AA
      – PersonEntity:
          Name:
            NameFull: Gasior M
      – PersonEntity:
          Name:
            NameFull: Devinsky O
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2022 May
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1474-4465
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: The Lancet. Neurology
              Type: main
ResultId 1